Beam Therapeutics (BEAM) Gains from Sales and Divestitures (2020 - 2026)
Beam Therapeutics (BEAM) reported Gains from Sales and Divestitures of $720697.0 for Q1 2026, up 18.69% year-over-year from $607196.0 in Q1 2025, and down 31.27% quarter-over-quarter from $1.0 million in Q4 2025.
Beam Therapeutics (BEAM) Gains from Sales and Divestitures (2020 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 7 years of Gains from Sales and Divestitures data on file, last reported at $720697.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $720697.0, up 18.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $720697.0 (up 18.69% YoY), and the FY2025 annual result was $1.0 million, down 19.46% from the prior year.
- Gains from Sales and Divestitures fell to $720697.0 in Q1 2026 per BEAM's latest filing, from $1.0 million in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $1.3 million in Q4 2024 and troughed at $283186.0 in Q1 2022.
- A 5-year average of $562691.0 and a median of $469531.0 in 2023 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2022 and 2024: Gains from Sales and Divestitures sank 58.44% in 2022, then soared 177.31% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $424303.0 in 2022, then climbed by 10.66% to $469531.0 in 2023, then soared by 177.31% to $1.3 million in 2024, then slipped by 19.46% to $1.0 million in 2025, then tumbled by 31.27% to $720697.0 in 2026.
- Business Quant data shows BEAM's Gains from Sales and Divestitures at $720697.0 in Q1 2026, $1.0 million in Q4 2025, and $783939.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 720,697.00 |
| Mar 31, 2026 | 720,697.00 |
| Dec 31, 2025 | 1.05 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | 783,939.00 |
| Sep 30, 2025 | 783,939.00 |
| Jun 30, 2025 | 688,359.00 |
| Jun 30, 2025 | 688,359.00 |
| Mar 31, 2025 | 607,196.00 |
| Mar 31, 2025 | 607,196.00 |
| Dec 31, 2024 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 575,358.00 |
| Sep 30, 2024 | 575,358.00 |
| Jun 30, 2024 | 492,619.00 |
| Jun 30, 2024 | 492,619.00 |
| Mar 31, 2024 | 420,579.00 |
| Mar 31, 2024 | 420,579.00 |
| Dec 31, 2023 | 469,531.00 |
| Dec 31, 2023 | 469,531.00 |